Real-World Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients

This retrospective cohort study evaluated the effectiveness and safety of Janus Kinase inhibitors (JAKi) in treating alopecia areata (AA) in 72 patients. It found that 61% of patients experienced substantial hair regrowth over a median follow-up of 16 months, with a median time to regrowth of 7 months. Cumulative regrowth rates increased to 59.7% at 12 months. Among those who switched medications after not initially responding, 75% achieved substantial regrowth. Two serious adverse events were reported. The study concludes that JAKi are effective and safe for AA treatment in real-world settings, but further prospective studies are needed to refine treatment guidelines.